Literature DB >> 29617844

Platform trials arrive on time for glioblastoma.

Brian M Alexander1, Timothy F Cloughesy2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29617844      PMCID： PMC5961158          DOI： 10.1093/neuonc/noy040

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  11 in total

1.  Preclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2-Amplified and TP53 Wild-type Glioblastomas.

Authors:  Maite Verreault; Charlotte Schmitt; Lauriane Goldwirt; Kristine Pelton; Samer Haidar; Camille Levasseur; Jeremy Guehennec; David Knoff; Marianne Labussière; Yannick Marie; Azra H Ligon; Karima Mokhtari; Khê Hoang-Xuan; Marc Sanson; Brian M Alexander; Patrick Y Wen; Jean-Yves Delattre; Keith L Ligon; Ahmed Idbaih
Journal:  Clin Cancer Res       Date:  2015-10-19       Impact factor: 12.531

2.  Bayesian Baskets: A Novel Design for Biomarker-Based Clinical Trials.

Authors:  Lorenzo Trippa; Brian Michael Alexander
Journal:  J Clin Oncol       Date:  2017-01-03       Impact factor: 44.544

3.  The somatic genomic landscape of glioblastoma.

Authors:  Cameron W Brennan; Roel G W Verhaak; Aaron McKenna; Benito Campos; Houtan Noushmehr; Sofie R Salama; Siyuan Zheng; Debyani Chakravarty; J Zachary Sanborn; Samuel H Berman; Rameen Beroukhim; Brady Bernard; Chang-Jiun Wu; Giannicola Genovese; Ilya Shmulevich; Jill Barnholtz-Sloan; Lihua Zou; Rahulsimham Vegesna; Sachet A Shukla; Giovanni Ciriello; W K Yung; Wei Zhang; Carrie Sougnez; Tom Mikkelsen; Kenneth Aldape; Darell D Bigner; Erwin G Van Meir; Michael Prados; Andrew Sloan; Keith L Black; Jennifer Eschbacher; Gaetano Finocchiaro; William Friedman; David W Andrews; Abhijit Guha; Mary Iacocca; Brian P O'Neill; Greg Foltz; Jerome Myers; Daniel J Weisenberger; Robert Penny; Raju Kucherlapati; Charles M Perou; D Neil Hayes; Richard Gibbs; Marco Marra; Gordon B Mills; Eric Lander; Paul Spellman; Richard Wilson; Chris Sander; John Weinstein; Matthew Meyerson; Stacey Gabriel; Peter W Laird; David Haussler; Gad Getz; Lynda Chin
Journal:  Cell       Date:  2013-10-10       Impact factor: 41.582

4.  Point/counterpoint: randomized versus single-arm phase II clinical trials for patients with newly diagnosed glioblastoma.

Authors:  Stuart A Grossman; Karisa C Schreck; Karla Ballman; Brian Alexander
Journal:  Neuro Oncol       Date:  2017-04-01       Impact factor: 12.300

5.  The clinical trials landscape for glioblastoma: is it adequate to develop new treatments?

Authors:  Alyssa M Vanderbeek; Rifaquat Rahman; Geoffrey Fell; Steffen Ventz; Tianqi Chen; Robert Redd; Giovanni Parmigiani; Timothy F Cloughesy; Patrick Y Wen; Lorenzo Trippa; Brian M Alexander
Journal:  Neuro Oncol       Date:  2018-07-05       Impact factor: 12.300

6.  Feasibility of real-time molecular profiling for patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation-the NCT Neuro Master Match (N2M2) pilot study.

Authors:  Elke Pfaff; Tobias Kessler; Gnana Prakash Balasubramanian; Anne Berberich; Daniel Schrimpf; Antje Wick; Jürgen Debus; Andreas Unterberg; Martin Bendszus; Christel Herold-Mende; David Capper; Irini Schenkel; Andreas Eisenmenger; Susan Dettmer; Benedikt Brors; Michael Platten; Stefan M Pfister; Andreas von Deimling; David T W Jones; Wolfgang Wick; Felix Sahm
Journal:  Neuro Oncol       Date:  2018-05-18       Impact factor: 12.300

Review 7.  Adaptive Global Innovative Learning Environment for Glioblastoma: GBM AGILE.

Authors:  Brian M Alexander; Sujuan Ba; Mitchel S Berger; Donald A Berry; Webster K Cavenee; Susan M Chang; Timothy F Cloughesy; Tao Jiang; Mustafa Khasraw; Wenbin Li; Robert Mittman; George H Poste; Patrick Y Wen; W K Alfred Yung; Anna D Barker
Journal:  Clin Cancer Res       Date:  2017-08-16       Impact factor: 12.531

Review 8.  Adult Glioblastoma.

Authors:  Brian M Alexander; Timothy F Cloughesy
Journal:  J Clin Oncol       Date:  2017-06-22       Impact factor: 44.544

Review 9.  Trial designs for personalizing cancer care: a systematic review and classification.

Authors:  Parvin Tajik; Aleiko H Zwinderman; Ben W Mol; Patrick M Bossuyt
Journal:  Clin Cancer Res       Date:  2013-06-20       Impact factor: 12.531

10.  Leveraging molecular datasets for biomarker-based clinical trial design in glioblastoma.

Authors:  Shyam K Tanguturi; Lorenzo Trippa; Shakti H Ramkissoon; Kristine Pelton; David Knoff; David Sandak; Neal I Lindeman; Azra H Ligon; Rameen Beroukhim; Giovanni Parmigiani; Patrick Y Wen; Keith L Ligon; Brian M Alexander
Journal:  Neuro Oncol       Date:  2017-07-01       Impact factor: 12.300
View more
  4 in total

Review 1.  Novel Clinical Trial Designs in Neuro-Oncology.

Authors:  Anurag Saraf; Lorenzo Trippa; Rifaquat Rahman
Journal:  Neurotherapeutics       Date:  2022-08-15       Impact factor: 6.088

2.  New directions in clinical trials for frontotemporal lobar degeneration: Methods and outcome measures.

Authors:  Adam L Boxer; Michael Gold; Howard Feldman; Bradley F Boeve; Susan L-J Dickinson; Howard Fillit; Carole Ho; Robert Paul; Rodney Pearlman; Margaret Sutherland; Ajay Verma; Stephen P Arneric; Brian M Alexander; Bradford C Dickerson; Earl Ray Dorsey; Murray Grossman; Edward D Huey; Michael C Irizarry; William J Marks; Mario Masellis; Frances McFarland; Debra Niehoff; Chiadi U Onyike; Sabrina Paganoni; Michael A Panzara; Kenneth Rockwood; Jonathan D Rohrer; Howard Rosen; Robert N Schuck; Holly D Soares; Nadine Tatton
Journal:  Alzheimers Dement       Date:  2020-01-06       Impact factor: 21.566

3.  MGMT testing always worth an emotion.

Authors:  Monika E Hegi; Koichi Ichimura
Journal:  Neuro Oncol       Date:  2021-09-01       Impact factor: 13.029

4.  Genome Medicine for Brain Tumors: Current Status and Future Perspectives.

Authors:  Akitake Mukasa
Journal:  Neurol Med Chir (Tokyo)       Date:  2020-10-16       Impact factor: 1.742
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.